Clinical trials: Lenalidomide
Multiple Myeloma
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
The purpose of this study is to determine whether giving linvoseltamab with lenalidomide during maintenance treatment to participants with multiple myeloma will: 1.
- Trial name
- NCT06910124
- Testing
- Linvoseltamab, Lenalidomide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Dickran Kazandjian, MD
Diffuse Large B-Cell Lymphoma
G-Pola-ZLP in Diffuse Large B-Cell Lymphoma
The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-ZLP as induction therapy in patients with DLBCL.
- Trial name
- NCT06665217
- Testing
- Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy
- Volunteers
- 80 people
- Sponsor
- Navy General Hospital, Beijing
NK/T Cell Lymphoma
PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma
To observe the safety, tolerability and clinical effects of PD-1 Antibody, Chidamide, Lenalidomide and Etoposide in Relapsed or Refractory NK/T cell Lymphoma.
- Trial name
- NCT04038411
- Testing
- PD-1 Antibody, chidamide, lenalidomide and etoposide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Mingzhi Zhang
Peripheral T-cell Lymphoma
PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma
To observe the safety, tolerability and clinical effects of PD-1, chidamide, lenalidomide and gemcitabine in the treatment of newly diagnosed and relapse/refractory peripheral T-cell lymphoma.
- Trial name
- NCT04040491
- Testing
- PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Mingzhi Zhang
Refractory Multiple Myeloma, Smoldering Multiple Myeloma
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
RATIONALE: Melphalan, a chemotherapeutic agent, has been found to be an effective treatment choice for destroying myeloma cells, especially when given at high (bone marrow ablative) doses.
- Conditions
- Refractory Multiple Myeloma, Smoldering Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma
- Trial name
- NCT00112827
- Testing
- total marrow irradiation, melphalan, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- City of Hope Medical Center
Central Nervous System Tumors
Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors
Independently, both lenalidomide and vorinostat have shown promising activity in pediatric central nervous system (CNS) tumors. These are both agents that are not typically part of first-line studies, although both agents are of…
- Trial name
- NCT03050450
- Testing
- 25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®), 50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®), 100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Johns Hopkins All Children's Hospital
EBV-Associated Lymphoproliferative Disorders, PD-1 Inhibitor
Application of PD-1 Inhibitors, Tenofovir, Chidamide, and Lenalidomide in Relapsed/Refractory EBV-associated Lymphoproliferative Disorders.
This study is a prospective, multicenter, single-arm clinical trial designed to evaluate the efficacy and safety of PD-1 inhibitor combined with tenofovir, chidamide, and lenalidomide in the treatment of relapsed or refractory…
- Conditions
- EBV-Associated Lymphoproliferative Disorders, PD-1 Inhibitor, Tenofovir, Chidamide
- Trial name
- NCT07133763
- Testing
- PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV-Associated Lymphoproliferative Disorders.
- Volunteers
- 50 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
EBV Infection
PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV
The present study was a prospective one-arm clinical study, in which EBV-HLH/chronic active EBV infection patients were selected as the main subjects to evaluate the effect of PD-1 antibody and lenalidomide regimens on ebv-dna…
- Trial name
- NCT04084626
- Testing
- PD1 antibody, lenalidomide
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Beijing Friendship Hospital
Lymphoma
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
The goal of this clinical research study is to find the highest tolerable dose of lenalidomide that can be given in combination with vorinostat, gemcitabine, busulfan, and melphalan, with a stem cell transplant, and with or…
- Trial name
- NCT02589145
- Testing
- Lenalidomide, Vorinostat, Gemcitabine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Age Range ≥16 Years, Gender Unlimited, Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma
Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL
This study was a prospective, multi-center, single-arm, Phase II clinical study. Compared with the literature data, objective response rate (ORR) and complete response rate (CR) were the primary endpoint, and 1-year and 2-year…
- Conditions
- Age Range ≥16 Years, Gender Unlimited, Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma, Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed, At Least One Positive Lesion According to the 2014 Lugano Criteria for Hodgkin's and Non-Hodgkin's Lymphoma
- Trial name
- NCT05050630
- Testing
- TR2-ICE
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q
In this trial, the investigators will test the combination of escalating doses of chemotherapy (starting at relatively low dose) with lenalidomide in intermediate-2-or high risk MDS and AML with del 5 q31.
- Conditions
- Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
- Trial name
- GFM-Chimio-Rev (NCT00885508)
- Testing
- Lenalidomide
- Where
- 25 sites in France
- Volunteers
- 85 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
NK Cells in Cord Blood Transplantation
This phase I trial studies the side effects and best way to give natural killer cells and donor umbilical cord blood transplant in treating patients with hematological malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
- Trial name
- NCT01619761
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose of lenalidomide that can be given in combination with azacitidine to patients with MDS or AML.
- Trial name
- NCT01038635
- Testing
- 5-Azacytidine, Lenalidomide
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- M.D. Anderson Cancer Center
Diffuse Large B-cell Lymphoma
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
The goal of this phase 2 trial is to test the safety and efficacy of zanubrutinib and lenalidomide as maintenance therapy in patients with DLBCL.
- Trial name
- NCT06503263
- Testing
- Zanubrutinib plus Lenalidomide as Maintenance Therapy
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Navy General Hospital, Beijing
Multiple Myeloma
SIL as Maintenance Therapy in Multiple Myeloma
The goal of this phase 2 trial is to test the safety and efficacy of selinexor combined with ixazomib and lenalidomide as maintenance therapy in patients with multiple myeloma.
- Trial name
- NCT06744894
- Testing
- Selinexor combined with Ixazomib and Lenalidomide as Maintenance Therapy
- Volunteers
- 50 people
- Sponsor
- Navy General Hospital, Beijing
Multiple Myeloma and Plasma Cell Neoplasm
Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00899080
- Testing
- gene expression analysis, reverse transcriptase-polymerase chain reaction, immunoenzyme technique
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Eastern Cooperative Oncology Group
Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma
Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas
Background: Children who are diagnosed with brain tumors known as high grade gliomas or diffuse intrinsic pontine gliomas are generally treated with radiation therapy and chemotherapy.
- Conditions
- Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, High Grade Glioma
- Trial name
- NCT01222754
- Testing
- Lenalidomide, XRT, 54-59.4 Gy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Autism
Efficacy and Safety of Lenalidomide for Treatment of Autistic Spectrum Disorders
The purpose of this study is to determine if lenalidomide (Revlimid®)reduces proinflammatory cytokines including TNF-alpha and may actually alter the clinical course of autism for some children.
- Trial name
- NCT00996931
- Testing
- lenalidomide
- Volunteers
- 6 people
- Sponsor
- Sutter Medical Foundation
Chronic Lymphocytic Leukemia, CLL
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
The study is a two-arm, multi-center trial of Revlimid® and Rituximab, for the frontline treatment of patients with Chronic Lymphocytic Leukemia (CLL) designed and conducted by the CLL Research Consortium (CRC).
- Conditions
- Chronic Lymphocytic Leukemia, CLL, Untreated, Front-line
- Trial name
- NCT00628238
- Testing
- Lenalidomide and Rituximab
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- Chronic Lymphocytic Leukemia Research Consortium
Ovarian Cancer, Epithelial Ovarian Cancer
Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
This study will test the feasibility of combining 3 drugs, Revlimid with Doxil and Bevacizumab,and gather preliminary data on the potential activity of the combination in patients with platinum resistant/refractory ovarian cancer.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT01202890
- Testing
- Lenalidomide, Liposomal Doxorubicin, Bevacizumab, Revlimid, Doxil, Avastin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- New Mexico Cancer Research Alliance